Genome Editing Market Size To Reach $25.00 Billion By 2030

May 2024 | Report Format: Electronic (PDF)

Genome Editing Market Growth & Trends

The global genome editing market size is expected to reach USD 25.00 billion by 2030, exhibiting a CAGR of 16.94% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing advancements in genome editing technology, the growing funding & investments in the genomics industry, the increasing prevalence of genetic disorders, and the need for improved treatments and therapies are major factors driving revenue growth.

The evolution of genome editing technologies is another contributing factor to drive revenue growth in the market. Most effective and accurate gene editing is now possible through the enhancement of new and advanced genome editing methods including CRISPR-Cas13,prime editing, and base editing, amongst others. This creates genome editing methods used more often in academic and medical contexts. For instance, in January 2020, ERS Genomics and New England Biolab collaborated to develop and commercialize CRISPR gene modification tools & reagents.

The increasing application of gene-modification tools in therapeutic research has resulted in the rising number of advanced therapeutics entering clinical trials. Furthermore, the use of artificial intelligence to advance the implementation of novel gene modification systems exhibits great potential for the technology developer. This is anticipated to greatly favor revenue generation in the foreseeable future. Research communities are exploring the potential of gene-modification instruments such as CRISPR as a potential fast screening solution for various chronic diseases. Such research programs are likely to benefit the market for genome editing in the coming years.

key Request a free sample copy or view report summary: Genome Editing Market Report

Genome Editing Market Report Highlights

  • By technology, The CRISPR/Cas9 segment held the largest market share of 43.52% of the global revenue in 2023.

  • The ex-vivo segment dominated the market with a share of 51.24% in 2023. This dominance can be attributed to the ease of control in DNA modification provided along with the precise regulation of strength and duration of nuclease expression to minimize off-target editing and maximize efficiency.

  • The genetic engineering segment held the largest market share in 2023. The segment is further categorized into cell line engineering, animal genetic engineering, plant genetic engineering, and others.

  • The contract segment dominated the market in 2023 due to the high extent of outsourcing activities in the genomics space driven by the lower costs and greater flexibility in operations offered by such activities as compared to in-house development.

  • The biotechnology and pharmaceutical companies segment accounted for the largest market share of 50.95% in 2023.

  • North America dominated the market and accounted for a 47.81% share in 2023 owing to the growing investments in the R&D of gene editing technologies.

Genome Editing Market Segmentation

Grand View Research has segmented the global genome editing market report based on technology, delivery method, application, mode, end-use, and region:

Genome Editing Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • (CRISPR)/Cas9

  • TALENs/MegaTALs

  • ZFN

  • Meganuclease

  • Others

Genome Editing Delivery Method Outlook (Revenue, USD Million, 2018 - 2030)

  • Ex-vivo

  • In-vivo

Genome Editing Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Genetic Engineering

    • Cell line engineering

    • Animal genetic engineering

    • Plant genetic engineering

    • Others

  • Clinical Applications

    • Diagnostics

    • Therapy Development

Genome Editing Mode Outlook (Revenue, USD Million, 2018 - 2030)

  • Contract

  • In-house

Genome Editing End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Biotechnology and pharmaceutical companies

  • Academic and government research institutes

  • Contract research organizations

Genome Editing Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

List of Key Players of Genome Editing Market

  • Merck KGaA

  • Cibus Inc.

  • Recombinetics

  • Sangamo Therapeutics

  • Editas Medicine

  • Precision BioSciences

  • CRISPR Therapeutics

  • Intellia Therapeutics, Inc.

  • Caribou Biosciences, Inc

  • Cellectis S.A.

  • AstraZeneca

  • Takara Bio Inc.

  • Horizon Discovery Ltd. (Revvity, Inc.)

  • Danaher Corporation

  • Transposagen Biopharmaceuticals, Inc.

  • Genscript Biotech Corp

  • New England Biolabs

  • OriGene Technologies, Inc.

  • bluebird bio, Inc.

  • Lonza

  • Thermo Fisher Scientific, Inc

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.